The Company’s DepoVax™ platform is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Immunovaccine has advanced two DepoVax™-based cancer vaccines into Phase 1 human clinical trials. The Company is also advancing a broad infectious diseases pipeline including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax. In addition to the Company’s human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has key partnerships in the animal health sector including an agreement with Zoetis, former animal health division of Pfizer.
Halifax, CA
23 (est)

Key People at Immunovaccine

Kimberly Stephens

Kimberly Stephens

Marc Mansour

Marc Mansour


Immunovaccine Locations

Halifax, CA

Immunovaccine Metrics

Immunovaccine Summary

Founding Date


Market capitalization

$82.2 M

Closing share price


Immunovaccine Market Value History

Immunovaccine Online Presence

Immunovaccine News

Immunovaccine Company Life